Sign in
← Compounds

Rapamycin (Sirolimus)

off-label Rx · co-headlineFDA-approved · off-label

mTORC1 inhibition; autophagy; geroscience

Summary

Rapamycin (sirolimus) — mTOR inhibitor and the most-studied off-label geroscience drug. Intermittent weekly dosing targets mTORC1 for healthspan/immune modulation while limiting the immunosuppression of daily transplant dosing. Requires real clinician oversight.

How it works

  • mTORC1 inhibition
  • Autophagy induction
  • Cellular senescence / immune modulation

Dosing

  • unit: mg
    frequency: once weekly (pulsed)
    standard dose: 6
    administration route: Oral

Cycling

  • Weekly pulse; periodic breaks per clinician

Side effects

common: ["Aphthous mouth ulcers","Transient lipid/glucose elevation","GI upset"]
warnings: ["Immunosuppression / infection risk","Impaired wound healing","Hold around live vaccines and surgery"]

Verified citations

3 · PubMed-checked
  • Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.preclinicalPMID 19587680 ↗
  • Targeting ageing with rapamycin and its derivatives in humans: a systematic review.clinicalPMID 38310895 ↗
  • Targeting the biology of aging with mTOR inhibitors.reviewPMID 37142830 ↗

Used for

Legal / compounding

FDA-approved · off-label

Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.